In the second part of this course Professor Correll will review the complex pharmacology of clozapine thought to underly its unique efficacy and safety profile. He will dissect the different mechanisms of action which could be leveraged as molecular targets for innovative antipsychotic agent development and review clinical translational aspects, including tolerability and efficacy. Professor Paola Dazzan, will ask “Is our mistake trying to identify a “homogeneous” schizophrenia construct?” While some pathophysiological processes are common to schizophrenia subtypes, others vary widely. Enhanced statistical approaches, such as factor analysis or machine learning, can aid the study of schizophrenia as a complex and heterogeneous disorder, as can novel methodologies taking varying biological or psychosocial contributors into account. Flexible time-points may better capture fluctuating changes in biological systems during symptomatic relapse or while in recovery. Exploring and implementing these different approaches can help disentangle the heterogeneity of schizophrenia. Professor Sir Robin Murray will present findings from the INTREPID study of Psychosis in the Global South; a multi-study programme of research in India, Nigeria and Trinidad studying the incidence, risk factors, phenomenology, aetiology, course, help-seeking, impact and outcomes of psychotic disorders in diverse settings.

During this session you will

Chair: Dr Fiona Gaughran, National Psychosis Service, South London and Maudsley NHS Foundation Trust, London, United Kingdom

Clozapine 2023: translating molecular targets to clinical outcomes

Christoph Correll, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA

Does brain structure and function causally determine mental disorder?

Dr Paola Dazzan, King's College London, London, United Kingdom

The INTREPID study of Psychosis in the Global South

Professor Sir Robin Murray, King's College London, London, United Kingdom